Home Message from CEO About US Business Operations Features of Our Technology Contact
ImmunoFrontier prepared the CSR of Phase I Study of CHP-NY-ESO-1 in patients with Malignancies Expressing NY-ESO 1 in US.
ImmunoFrontier completed the CSR of Phase I Study of CHP-NY-ESO-1 in Patients with Refractory Esophageal Cancer Expressing NY-ESO 1 in Japan.
FDA approved Phase I Study of IMF-001 in US.
ImmunoFrontier filed an IND application of IMF-001 for Phase I Study in US.
Aug. 17, 2009
ImmunoFrontier filed an Application of CHP-NY-ESO-1 for Phase I Study with PMDA to develop for esophageal cancer.
Mar.10, 2009
CHP-NY-ESO-1 project was chosen for NIBIO's "Practical Application Research Supporting Program for Medicine and Medical Device".
Mar.9, 2009
ImmunoFrontier was reported in International Pharmaceutical Intelligence as challenging company titled "Developing vaccines and immunotherapeutic drugs based on CHP".
Site Map Japanese